Damora Therapeutics, Inc.
NASDAQ:DMRABiotechnology
+$0.07 today
- Market cap
- $1.42B
- Beta
- 1.48
- P/E (TTM)
- -0.1
- EPS (TTM)
- -$177.15
Volume 0.58M
Average 0.33M
DMRA Other Current Assets
Current assets not reported separately, such as prepaid expenses.
Damora Therapeutics, Inc.NASDAQ: DMRA
Other Current Assets · Q1 FY2026 · quarter ended Mar 2026
Other current assets rises 826.9% from a year ago
Other current assets stood at $1.21M at the end of Q1 FY2026, up 826.9% from a year earlier and down 8.9% from the prior quarter. Over 3 fiscal years it compounded at -4.1% a year.
Context
- Other current assets amounted to 0.2% of total assets at the end of Q1 FY2026, down 0.6 pp from a year earlier.
- Other current assets increased in 2 of the last 3 fiscal years.
What to watch
Whether other current assets keeps rising in the next quarterly balance sheet after a +826.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 1.32M USD
- Year-over-year change
- +10.9%
- 4-year CAGR
- -31.2%
| Period | Period end | Other Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.32M | +10.9% |
| FY2024 | 2024-12-31 | 1.19M | +5.5% |
| FY2023 | 2023-12-31 | 1.13M | -24.7% |
| FY2022 | 2022-12-31 | 1.5M | -74.6% |
| FY2021 | 2021-12-31 | 5.9M | — |
Other Current Assets vs competitors
How DMRA compares with its peers on the latest reported figures
- DMRA's Mar 2026 other current assets of $1.21M is the 6th highest of the 9 companies compared; the peer median is $11.82M.
- Its year-over-year change of +826.9% is the 2nd highest of 7, against a peer median of +8.0%.
- Other current assets amounts to 0.2% of total assets for DMRA, versus a peer median of 1.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $140.15M | +1513.3% | +203.1% | 26.2% | |
| Jun 2026 | $91.94M | -68.9% | +23.9% | 1.2% | |
| Mar 2026 | $25.75M | +303.8% | +38.5% | 5.1% | |
IRONDisc Medicine, Inc. | Sep 2026 | $14.59M | +29.7% | — | 2.1% |
| Mar 2026 | $9.04M | -13.6% | +36.0% | 1.2% | |
DMRADamora Therapeutics, Inc. | Mar 2026 | $1.21M | +826.9% | -4.1% | 0.2% |
| Mar 2026 | $1.04M | -64.8% | +105.6% | 0.3% | |
| Jun 2026 | $0 | — | -99.7% | 0.0% | |
COAGHemab Therapeutics Holdings, Inc. Common Stock | Jun 2026 | $0 | — | — | 0.0% |
| Peer median (excluding DMRA) | $11.82M | +8.0% | +37.2% | 1.2% | |
Competitors are the stored peer set for DMRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 62.56M | 32.79M | 21.47M | 14.18M | 257.62M |
| Short-term Investments | 37.63M | 27.44M | 11.69M | 0 | 0 |
| Net Receivables | 2.28M | 1.38M | 1.72M | 881K | 899K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 5.9M | 1.5M | 1.13M | 1.19M | 1.32M |
| Total Current Assets | 110.1M | 63.91M | 36.77M | 16.84M | 260.42M |
| Property, Plant & Equipment (Net) | 1.04M | 1.17M | 325K | 130K | 104K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 9.05M | 5.83M | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 2.03M | 2.28M | 1.13M | 163K | 0 |
| Total Non-current Assets | 12.11M | 9.28M | 1.45M | 293K | 104K |
| Total Assets | 122.22M | 73.19M | 38.23M | 17.13M | 260.53M |
| Account Payables | 1.53M | 3.35M | 1.7M | 377K | 444K |
| Short-term Debt | 399K | 476K | 183K | 12K | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 2.01M | 6.68M | 2.96M | 604K | 1.52M |
| Total Current Liabilities | 4.54M | 11.11M | 5.83M | 1.2M | 20.07M |
| Long-term Debt | 0 | 0 | 0 | 1.36M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 43K | 28K |
| Total Non-current Liabilities | 448K | 328K | 66K | 1.46M | 81K |
| Total Liabilities | 4.99M | 11.44M | 5.9M | 2.66M | 20.15M |
| Common Stock | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | (156.11M) | (217.74M) | (256.08M) | (277.52M) | (487.36M) |
| Accumulated OCI | (320K) | (244K) | 380K | 97K | 802K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 117.22M | 61.75M | 32.33M | 14.47M | 240.38M |
| Total Debt | 847K | 804K | 249K | 1.43M | 68K |
| Net Debt | (61.72M) | (31.98M) | (21.22M) | (12.74M) | (257.56M) |
Damora Therapeutics, Inc.
NASDAQ:DMRA
Intrinsic Alpha fair value
Locked
Current Price
$22.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.